Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT02152761
- Phase
- PHASE2
- Status
- Completed
Conditions
- Muscle Wasting (Atrophy) After Hip Fracture Surgery
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bimagrumab — DRUGBimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
- placebo — OTHERMatching placebo was administered as intravenous infusion starting on Day 1 until week 20.
Study Details
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
Key Dates
- Start date
- Sep 16, 2014
- Status verified
- Aug 2020
- Primary completion
- May 14, 2018
- Completion
- Oct 25, 2018
Study Design
- Enrollment
- 251 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: bimagrumab 700 mgApproximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
- Experimental: bimagrumab 210 mgApproximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
- Placebo Comparator: placeboApproximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
- Experimental: Bimagrumab 70 mgApproximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
Primary Outcome Measure
Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 [ Time Frame: baseline, weeks 12 and 24 ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85023 | - |
| Novartis Investigative Site | El Cajon | California | 92020 | - |
| Novartis Investigative Site | Denver | Colorado | 80210 | - |
| Novartis Investigative Site | Gainesville | Georgia | 30501 | - |
| Novartis Investigative Site | Rochester | Minnesota | 55905 | - |
| Novartis Investigative Site | New York | New York | 10021 | - |